174074-89-6

Basic information

• Product Name: Methyl2,4-dichloroquinazoline-7-carboxylate
• Synonyms: Methyl2,4-dichloroquinazoline-7-carboxylate
• CAS NO: 174074-89-6
• Molecular Formula: C₁₀H₆Cl₂N₂O₂
• Molecular Weight: 257.075
• Mol File: 174074-89-6.mol

Chemical Properties

• Boiling Point: 303.3 °C at 760 mmHg
• Flash Point: 137.3 °C
• Appearance: /
• Density: 1.496 g/cm³
• Refractive Index: 1.639
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.38±0.30(Predicted)
• CAS DataBase Reference: Methyl2,4-dichloroquinazoline-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl2,4-dichloroquinazoline-7-carboxylate(174074-89-6)
• EPA Substance Registry System: Methyl2,4-dichloroquinazoline-7-carboxylate(174074-89-6)

Safety Data

• Hazardous Substances Data: 174074-89-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 2,4-dichloroquinazoline-7-carboxylate is used as a key intermediate in organic synthesis for the preparation of various chemical compounds. Its unique structure and functional groups make it a versatile building block for creating a wide range of molecules with diverse properties and applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Methyl 2,4-dichloroquinazoline-7-carboxylate is employed as a starting material for the synthesis of pharmaceutical compounds. Its quinazoline core and functional groups can be modified to generate new molecules with potential therapeutic effects. Methyl2,4-dichloroquinazoline-7-carboxylate's specific properties and potential applications in this field would depend on its individual characteristics and the context in which it is used.
Used in Drug Discovery:
Methyl 2,4-dichloroquinazoline-7-carboxylate is utilized in drug discovery processes as a potential scaffold for the development of new drugs. Its unique chemical structure and functional groups can be optimized to target specific biological pathways or receptors, leading to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Chemical Research:
Methyl2,4-dichloroquinazoline-7-carboxylate is also used in chemical research to study the properties and reactivity of quinazoline derivatives. Understanding the behavior of Methyl 2,4-dichloroquinazoline-7-carboxylate in various chemical reactions can provide valuable insights into the design and synthesis of new molecules with specific functions and applications.

InChI:InChI=1/C10H6Cl2N2O2/c1-16-9(15)5-2-3-6-7(4-5)13-10(12)14-8(6)11/h2-4H,1H3

Upstream product

• 5372-81-6 dimethyl aminoterephthalate 
• 174074-88-5 2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid methyl ester 
• 174074-88-5 methyl 2,4-dihydroxyquinazoline-7-carboxylate 

Downstream Products

• 953039-79-7 methyl 2-chloroquinazoline-7-carboxylate 
• 1374203-86-7 4-(3-(4-(7-(2-hydroxypropan-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)-N,N-dimethyl-benzamide 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).

QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS

The present invention relates to quinazoline compounds of formula (I) useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. or a pharmaceutically acceptable derivative thereof, wherein R1, X, R3, x, and ring A are as defined in the present application.